AAP
ATNM icon

Arax Advisory Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Arax Advisory Partners’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-707
Closed -$962 – 3812
2025
Q4 		$962 Buy
707
+673
+1,979% +$982 ﹤0.01% 3489
2025
Q3 		$54 Buy
+34
New +$55 ﹤0.01% 3529
2024
Q4 		– Sell
-126
Closed -$237 – 2458
2024
Q3 		$237 Hold
126
– – ﹤0.01% 2500
2024
Q2 		$933 Buy
+126
New +$1.04K ﹤0.01% 2191

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's ATNM Position: Q1 2026 in Review

Arax Advisory Partners sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 707 shares — an estimated $962 sold.

Arax Advisory Partners first reported a position in ATNM in Q2 2024 and held it in 4 quarters. The position peaked at $962 in Q4 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Arax Advisory Partners reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 707 Actinium Pharmaceuticals shares in Q1 2026, an estimated $962.
  • Arax Advisory Partners first reported a position in Actinium Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Arax Advisory Partners's Actinium Pharmaceuticals position peaked at $962 in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.